Rituximab

{
  "id": "MLC-T-ONC-007472",
  "term": "Rituximab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs under the brand names Riabni, Rituxan, Ruxience, and Truxima to treat certain types of B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and B-cell acute leukemia that are CD20 positive. Rituximab is also being studied in the treatment of other conditions and types of cancer. Rituximab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Rituximab is a type of monoclonal antibody.",
    "A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells."
  ],
  "synonyms": [
    "rituximab-arrx",
    "rituximab biosimilar BI 695500",
    "rituximab biosimilar SIBP-02",
    "rituximab ARRX",
    "rituximab-pvvr",
    "chimeric anti-CD20 antibody",
    "IDEC-C2B8 monoclonal antibody",
    "rituximab biosimilar SAIT101",
    "C2B8 monoclonal antibody",
    "rituximab PVVR",
    "rituximab biosimilar RTXM83",
    "rituximab biosimilar PF-05280586",
    "monoclonal antibody IDEC-C2B8",
    "rituximab biosimilar IBI301",
    "rituximab biosimilar TQB2303",
    "rituximab ABBS",
    "rituximab biosimilar ABP 798",
    "rituximab biosimilar GB241",
    "rituximab biosimilar CT-P10",
    "rituximab-abbs"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/rituximab/"
}